Draft:Netanel Korin

Netanel Korin (Hebrew:נתנאל קורין, born 1974) is a professor of cardiovascular nanomedicine engineering at the Biomedical Engineering Faculty of the Technion - Israel Institute of Technology. He currently serves as an associate professor and previously held the position of vice dean of the faculty.

Biography
Milman born on January 12, 1977, in Israel. He completed his Bachelor's degree in Mechanical Engineering (BSc) at Ben-Gurion University of the Negev in 1996. In 2005 he received a Master's degree (MSc) from the Biomedical Engineering Faculty at the Technion, and in 2008 he obtained his PhD from the same faculty. Between 2008-2014 he did his postdoctoral research at the Wyss Institute for Biologically Inspired Engineering at MIT.

Professor Korin is a leading researcher in the field of cardiovascular nanomedicine. His research focuses on developing nanomedicine technologies for the prevention and treatment of cardiovascular diseases, such as anti-thrombotic drugs and flow-targeted fibrinolytic agents. He is a pioneer in developing microfluidic systems to study biological processes and biomimetic models of blood vessels.

To date, Prof. Korin has published 59 research papers, including 47 scientific articles and 7 review papers. His work has been extensively cited, with thousands of citations, and featured in various media outlets, including a prominent 2012 paper published in the journal Science. He has collaborated with leading researchers from institutions such as Harvard, MIT, Boston University, and others.

Patents and Inventions
Professor Korin holding several important patents. Among others, Korin has filed for patents on technologies such as targeted drug delivery for treating stenosis and thrombotic phenomena in blood vessels, nanotherapeutics for ischemic stroke treatment, and biomimetic systems for studying lung diseases. One patent published in 2023 describes an innovative heart valve designed to mitigate blood stagnation and reduce the risk of clot formation. The proposed technologies developed by Korin aim to advance treatments for cardiovascular disorders through nanomedical approaches and biomimetic models replicating physiological conditions.

Notable patents include developing nanoparticles for ischemic stroke therapy (2021), biomimetic flow systems for lung diseases (2021, 2022), and a shear-activated nanotherapeutic for obstructed blood vessels (2015).

Awards and recognition
Among Korin's notable achievements are receiving a €150,000 Proof-of-Concept grant from the European Research Council in 2024